SCHEDULE: Sofinnova Crossover II Reports 5.4% Stake in Hemab Therapeutics

Sofinnova Crossover II SLP and associated entities have reported beneficial ownership of 5.4% of Hemab Therapeutics Holdings, Inc. common stock as of June 30, 2026.

Summary

• Sofinnova Crossover II SLP, along with its management company Sofinnova Partners SAS and investment committee members, has filed a Schedule 13G.
• The filing indicates beneficial ownership of 2,511,212 shares of Hemab Therapeutics Holdings, Inc. common stock.
• This represents 5.4% of the class of securities outstanding as of May 8, 2026.
• The reporting date for this ownership is June 30, 2026.
• The filing details the sole voting and dispositive power held by Sofinnova Crossover II SLP and Sofinnova Partners SAS, with shared power attributed to the investment committee members.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without new strategic or financial information.

Positives

• Significant institutional ownership by Sofinnova Crossover II SLP, indicating potential investor confidence.
• Clear disclosure of beneficial ownership, providing transparency to the market.

Negatives

• The filing does not contain new financial results or strategic updates, limiting its immediate impact on valuation.
• The ownership stake is reported based on historical outstanding share data from May 2026, which may not reflect current conditions.

Risks

• Potential for future changes in beneficial ownership by Sofinnova Crossover II SLP, which could impact share price.
• The investment committee members' shared power to vote and dispose of shares could lead to coordinated actions affecting the company.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance.

Management Comments

• The filing of this Schedule 13G shall not be construed as an admission by Papiernik, Moreau, Hong, Anderson and Evans that such person is, for the purposes of Section 13(d) of the Securities Exchange Act of 1934, the beneficial owner of any securities covered by this Statement.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors crossing certain ownership thresholds. Sofinnova Crossover II SLP is a known venture capital and growth equity firm, and their investment in Hemab Therapeutics, a biotechnology company, aligns with typical investment patterns in the sector.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant institutional ownership, potentially influencing market perception.
• Management: Awareness of a substantial shareholder's position and potential influence.
• Creditors: No direct impact indicated by this filing.

Next Steps

• Monitor future filings from Sofinnova Crossover II SLP for any changes in beneficial ownership.
• Observe Hemab Therapeutics Holdings, Inc. for any strategic announcements or financial reports.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Institutional Investor, Hemab Therapeutics, Sofinnova Crossover II SLP, Common Stock, Investment Committee